Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Pathophysiology/Complications

Serum Adiponectin Is Increased in Type 1 Diabetic Patients With Nephropathy

  1. Markku Saraheimo, MD12,
  2. Carol Forsblom, MD, DMSC12,
  3. Johan Fagerudd, MD, DMSC12,
  4. Anna-Maija Teppo, PHD1,
  5. Kim Pettersson-Fernholm, MD, DMSC12,
  6. Jan Frystyk, MD, DMSC, PHD3,
  7. Allan Flyvbjerg, MD, DMSC3,
  8. Per-Henrik Groop, MD, DMSC12 and
  9. on behalf of the FinnDiane Study Group
  1. 1Folkhälsan Institute of Genetics, Folkhälsan Research Center, Biomedicum Helsinki, Helsinki, Finland
  2. 2Division of Nephrology, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland
  3. 3Medical Department M (Diabetes and Endocrinology) and the Medical Research Laboratories, Aarhus University Hospital, Aarhus University, Aarhus, Denmark
  1. Address correspondence and reprint requests to Per-Henrik Groop, MD, DMSc, Folkhälsan Research Center, Biomedicum Helsinki (318b), Haartmaninkatu 8, P.O. Box 63, FIN-00014, University of Helsinki, Helsinki, Finland. E-mail: per-henrik.groop{at}helsinki.fi
Diabetes Care 2005 Jun; 28(6): 1410-1414. https://doi.org/10.2337/diacare.28.6.1410
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Abstract

OBJECTIVE—To elucidate whether serum adiponectin is associated with renal function, low-grade inflammatory markers, metabolic control, and insulin resistance in type 1 diabetic patients with and without nephropathy.

RESEARCH DESIGN AND METHODS—A total of 189 type 1 diabetic patients from the Finnish Diabetic Nephropathy Study were divided into three groups based on their urinary albumin excretion rate (AER): patients with normal AER (n = 66) had no antihypertensive medication, while patients with microalbuminuria (n = 63) or macroalbuminuria (n = 60) were all treated with an ACE inhibitor. Renal function was estimated with the Cockcroft-Gault formula. Adiponectin was measured by an in-house time-resolved immunofluorometric assay.

RESULTS—Adiponectin concentrations were higher in women than in men, but since there was no significant difference in sex distribution between the groups, data were pooled. Adiponectin concentrations were higher in patients with macroalbuminuria (19.8 ± 12.0 mg/l) than in patients with microalbuminuria (13.1 ± 4.8 mg/l) or normoalbuminuria (11.8 ± 4.2 mg/l). In a univariate analysis, adiponectin was positively associated with creatinine (r = 0.41; P < 0.0001), AER (r = 0.33; P < 0.0001), interleukin-6 (r = 0.22; P = 0.002), systolic blood pressure (r = 0.22; P = 0.004), HbA1c (r = 0.17; P = 0.02), total cholesterol (r = 0.16; P = 0.03), and HDL cholesterol (r = 0.16; P = 0.03) and negatively with estimated glomerular filtration rate (GFR; r = −0.52; P < 0.0001) and waist-to-hip ratio (WHR; r = −0.16; P = 0.03). In a multiple linear regression analysis including the above variables, estimated GFR, AER, and WHR were independently associated with adiponectin levels (r2 = 0.32).

CONCLUSIONS—Serum adiponectin concentrations are increased in type 1 diabetic patients with nephropathy, and levels are further associated with renal insufficiency.

  • AER, albumin excretion rate
  • CRP, C-reactive protein
  • ESRD, end-stage renal disease
  • GFR, glomerular filtration rate
  • IL-6, interleukin-6
  • WHR, waist-to-hip ratio

Diabetic nephropathy is associated with insulin resistance and low-grade inflammation in type 1 diabetes (1,2). Circulatory levels of adiponectin, a hormone that is secreted exclusively from the adipocytes (3), correlate negatively with insulin resistance (4–6), serum triglycerides, fasting serum insulin, and fasting plasma glucose concentrations (5–7). Low plasma adiponectin concentrations are found in obesity (8,9), type 2 diabetes (7,8), and in patients with coronary artery disease (7,10). Women have higher adiponectin concentrations than men (6,7), a difference that may be explained by the effect of testosterone (11). Weight reduction increases adiponectin in both diabetic and nondiabetic subjects (7). Interestingly, the thiazolidinediones (peroxisome proliferator–activated receptor γ agonists) have emerged as an effective treatment for insulin-resistant states (12), and one of the mechanisms may be their ability to stimulate adiponectin synthesis (13,14).

The fact that adiponectin may have an anti-inflammatory effect is supported by the reciprocal association between adiponectin and C-reactive protein (CRP) in patients with coronary atherosclerosis (15). Furthermore, interleukin-6 (IL-6) downregulates adiponectin gene expression in adipocytes (16), and in obese women plasma IL-6 and CRP concentrations are inversely associated with adiponectin (17).

Adiponectin concentrations have been shown to be consistently higher in patients with renal disease than in healthy control subjects (18,19), although such patients display insulin resistance and an increased risk of cardiovascular disease. The reason is still an open matter. However, in patients with advanced end-stage renal disease (ESRD), high adiponectin concentrations were associated with type 1 diabetes and lower visceral fat mass as well as with low CRP. It is noteworthy that of the 204 patients with ESRD studied, only 29 patients had type 1 diabetes, and adiponectin was determined in only 17 of them (19). Another study including 46 subjects showed elevated adiponectin in type 1 diabetic patients with short duration, normal creatinine, and still-measurable C-peptide (20). Although adiponectin seems to be elevated in type 1 diabetes both early after diagnosis of the disease and at a rather late stage of ESRD, it is not known whether adiponectin increases in type 1 diabetes in parallel with the severity of diabetic nephropathy and/or whether it is linked to factors interfering with the risk of cardiovascular disease, such as insulin resistance, unfavorable lipid profile, and chronic inflammation.

Accordingly, the aim of the study was to measure serum adiponectin concentrations in type 1 diabetic patients with different stages of diabetic nephropathy and to elucidate whether adiponectin is associated with renal function, low-grade inflammatory markers, metabolic control, and insulin resistance.

RESEARCH DESIGN AND METHODS

A total of 189 type 1 diabetic patients were selected from the ongoing, nationwide, multicenter Finnish Diabetic Nephropathy Study (FinnDiane) and divided into three groups according to their urinary albumin excretion rate (AER) in three consecutive overnight or 24-h urine collections. Normal AER was defined as an AER persistently <20 μg/min or <30 mg/24 h, microalbuminuria as an AER between 20 and 200 μg/min or 30 and 300 mg/24 h, and macroalbuminuria as an AER >200 μg/min or >300 mg/24 h in at least two out of three urine collections.

Type 1 diabetes was defined as an onset of diabetes before the age of 35 years and permanent insulin treatment initiated within 1 year of diagnosis. Patients with normal AER were required to have neither antihypertensive medication nor signs of cardiovascular disease. Patients with micro- and macroalbuminuria were required to receive treatment with ACE inhibitors to be representative of type 1 diabetic patients with micro- or macroalbuminuria in Finland. Thereafter, patients were primarily matched for sex and, secondly, for duration of diabetes. A total of 401 type 1 diabetic patients of the initial study population of 1,616 met these criteria, and from this cohort we randomly selected 189 with a duration of diabetes of at least 10 years. The ethical committees of all participating centers approved the study protocol. Written informed consent was obtained from each patient, and the study was performed in accordance with the Declaration of Helsinki as revised in 2000.

Data on medication, cardiovascular status, diabetes complications, hypertension, and cardiovascular disease were obtained using a standardized questionnaire, which was completed by the patient’s attending physician based upon medical files. Blood pressure was measured twice in the sitting position with a mercury sphygmomanometer after at least a 10-min rest. Height and weight were recorded, and blood was drawn for the measurements of HbA1c, lipids, creatinine, inflammatory markers, and adiponectin.

HbA1c and lipids were measured by enzymatic methods at the local hospitals. Serum creatinine was determined using a modified Jaffé reaction. We calculated the estimated glucose disposal rate as a surrogate measure of insulin sensitivity with an equation developed by Williams et al. (21) and modified for HbA1c. In addition to AER, we estimated glomerular filtration rate (GFR) by using the Cockroft-Gault formula (22). CRP was measured by radioimmunoassay and IL-6 by high-sensitivity enzyme immunoassay as previously described (2).

Serum adiponectin was determined by a novel in-house time-resolved immunofluorometric assay based on two monoclonal antibodies and recombinant human adiponectin (R&D Systems, Abingdon, U.K.) as recently described (23). Adiponectin has a molecular weight of ∼30–36 kDa depending on the degree of glycosylation, but the molecule is known to form a wide range of polymers in vivo. The predominant polymers include trimers, hexamers, and highly congregated multimers of ∼300 kDa (24). Both of these antibodies were able to detect several adiponectin polymers in serum, including the three major molecular forms (data not shown). Within and in-between assay coefficients of variation of standards and unknown samples averaged <5 and 10%, respectively.

Statistical analysis

Data are expressed as means ± SD for normally distributed values and median (range) for nonnormally distributed values. Frequencies are given as percentages. Differences among groups for normally distributed variables were tested using ANOVA, and nonparametric data were analyzed using the Kruskal-Wallis and Mann-Whitney U test. Correlations were calculated using the Pearson correlation coefficient. Multiple linear regression analyses with adiponectin, AER, and estimated GFR as the dependent variable were used to assess independent relationships. The distribution of triglycerides, creatinine, AER, CRP, IL-6, and adiponectin were all skewed and therefore logarithmically transformed before analyses. All calculations were performed with a BMDP statistical package (Biomedical Data Processing Statistical Software, Los Angeles, CA). P values <0.05 were considered statistically significant.

RESULTS

The clinical characteristics of the patient population are shown in Table 1. The adiponectin concentrations were higher in women than in men. However, since there was no difference in sex distribution among the groups, data were pooled. Adiponectin concentrations were higher in patients with macroalbuminuria than in patients with microalbuminuria (P < 0.001) or normoalbuminuria (P < 0.0001) (Fig. 1). No difference was observed between patients with normoalbuminuria or microalbuminuria (P = 0.2). Adiponectin was positively associated with creatinine (r = 0.41; P < 0.0001), AER (r = 0.33; P < 0.0001), IL-6 (r = 0.22; P = 0.002), systolic blood pressure (r = 0.21; P = 0.004), HbA1c (r = 0.17; P = 0.02), total cholesterol (r = 0.16; P = 0.03), and HDL cholesterol (r = 0.16; P = 0.03) and negatively with estimated GFR (r = −0.52; P < 0.0001) and waist-to-hip ratio (WHR, r = −0.16; P = 0.03) in a univariate analysis. No association was observed with age, duration of diabetes, BMI, diastolic blood pressure, estimated glucose disposal rate, triglyceride, or CRP (data not shown). In a multiple linear regression analysis, including all variables that were associated with adiponectin in the univariate analysis, estimated GFR, AER, and WHR were independently associated with adiponectin concentrations (r2 = 0.32) (Table 2). On the other hand, in a similar analysis when AER was used as dependent variable, adiponectin, WHR, estimated GFR, and estimated glucose disposal rate were independently associated with AER (r2 = 0.46) (Table 3). With estimated GFR as dependent variable, adiponectin, AER, and HbA1c were independently associated with GFR (r2 = 0.26) (Table 4).

CONCLUSIONS

The major new finding in this study is the demonstration of markedly increased serum concentrations of adiponectin in type 1 diabetic patients with overt nephropathy and further that adiponectin is associated with renal insufficiency. On the contrary, there was no independent association between adiponectin and inflammatory markers in this patient population, which is in contrast to the findings in predialytic patients with ESRD (19) but in line with the findings in ESRD patients on dialysis (25). This may be due to the fact that patients with ESRD presumably have more confounding factors, like polypharmacy and uremic toxins, that can have a more profound impact on adiponectin and inflammatory markers than a patient population with mildly impaired kidney function. Notably, a recent study (26) in patients with early stages of chronic nondiabetic kidney disease did not observe any relationship between adiponectin and CRP. Interestingly, we also found an association between adiponectin and WHR, a strong feature of insulin resistance, but not between adiponectin and more direct indices of insulin resistance.

Antihypertensive medication itself has been suggested to have an effect on adiponectin (27). In a small group of patients (n = 16) with essential hypertension, treatment with an ACE inhibitor or an angiotensin II receptor blocker was associated with an increase in adiponectin. In our study, all micro- and macroalbuminuric patients were on an ACE inhibitor, whereas normoalbuminuric patients did not have any antihypertensive medication at all. If the increase in adiponectin would have been solely due to the ACE inhibition, a significant increase in adiponectin concentrations could have been expected in the patients with microalbuminuria as well.

The collagenous domain of the adiponectin molecule has four conserved lysines that can be hydroxylated and glycosylated. Both hydroxylation and glycosylation are suggested to be critical for the three-dimensional structure of the biologically active adiponectin molecule (28). It is likely that glycosylation is one of the major posttranslational modifications of adiponectin (28). In diabetic patients with constant hyperglycemia, the glycosylation process is probably altered, and this could lead to an altered adiponectin function. Consequently, a modified adiponectin molecule could lead to a diminished negative feedback, a mechanism that is an essential part of hormonal systems, and thus to increased adiponectin concentrations in diabetes.

An essential question to be answered is why advanced diabetic nephropathy is associated with increased concentrations of adiponectin. The opposite would be expected, since a typical feature of nephropathy is insulin resistance, which in type 2 diabetic patients has been associated with suppressed/low serum adiponectin concentrations (8). One possibility could be that the renal insufficiency per se further stimulates adiponectin production or alternatively leads to a defect in the clearance of adiponectin. The latter suggestion is supported by the finding that succesful kidney transplantation is followed by decreased plasma adiponectin concentrations (29). Although the true mechanisms responsible for the increase in circulating adiponectin in diabetic nephropathy are still unclear, one can speculate that adiponectin itself may have a role in mitigating the micro- and macrovascular burden in diabetic nephropathy, like it has been suggested to do in ESRD (25). Interestingly, adiponectin has been shown to be associated with endothelium-dependent vasodilatation (30) and, further, to modulate endothelial function by inhibiting the deleterious effects of tumor necrosis factor-α (10).

Proteinuria has been shown to be positively associated with adiponectin in patients with the nephrotic syndrome, although that study could not detect any association between GFR and adiponectin (18). In another study (19) including both type 1 and type 2 diabetic patients with ESRD, there was neither any association between AER and adiponectin nor between GFR and adiponectin. Our results show that not only AER but also estimated GFR is independently associated with increased adiponectin concentrations in type 1 diabetic patients with nephropathy. The question arises as to why our results differ from previous studies. The most plausible explanation is the inclusion of different patient populations as well as the number of type 1 diabetic patients, which was significantly higher in our study than in the previous studies. Notably, in a recent study in type 2 diabetic Pima Indians, adiponectin was associated with elevated serum creatinine and macroalbuminuria (31).

In conclusion, serum adiponectin concentrations are increased in type 1 diabetic patients with nephropathy, and levels are further associated with renal insufficiency. The reason why insulin-resistant conditions like proteinuria and advanced nephropathy are associated with high circulating adiponectin levels is still unclear.

Figure 1—
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1—

Adiponectin concentration (mg/l) in all type 1 diabetic patients as well as men and women. Data are means ± SD. Patients with normoalbuminuria (□), microalbuminuria (▒), and macroalbuminuria (▪). P values represent difference among the three groups (Kruskal-Wallis).

View this table:
  • View inline
  • View popup
Table 1—

Clinical characteristics of 189 type 1 diabetic patients

View this table:
  • View inline
  • View popup
Table 2—

Multiple regression analysis with adiponectin as dependent variable

View this table:
  • View inline
  • View popup
Table 3—

Multiple regression analysis with AER as dependent variable

View this table:
  • View inline
  • View popup
Table 4—

Multiple regression analysis with GFR (Cockroft-Gault) as dependent variable

Acknowledgments

The study was supported by grants from the Folkhälsan Research Foundation, Samfundet Folkhälsan, the Wilhelm and Else Stockmann Foundation, the Liv och Hälsa Foundation, the Finnish Medical Society (Finska Läkaresällskapet), European Commission (Euragedic), the National Danish Research Council, and the Danish Diabetes Association awards.

Part of this study was published in abstract form at the American Society of Nephrology meeting 2004. The skillful assistance of the Finnish Diabetic Nephropathy Study Group (previously presented in detail [2]) is acknowledged.

Footnotes

  • A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

    • Received November 11, 2004.
    • Revision received February 14, 2005.
  • DIABETES CARE

References

  1. ↵
    Orchard TJ, Chang Y, Ferrell RE, PetroN, Ellis DE: Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Kidney Int 62: 963–970, 2002
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    Saraheimo M, Teppo AM, Forsblom C, Fagerudd J, Groop PH: Diabetic nephropathy is associated with low-grade inflammation in type 1 diabetic patients. Diabetologia 46:1402–1407, 2003
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    Scherer P, Williams S, Fogliano M, Baldini G, Lodish H: A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270:26746–26749, 1995
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Berg A, Combs T, Du X, Brownlee M, Scherer P: The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7:947–953, 2001
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    Matsubara M, Maruoka S, Katayose S: Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. Eur J Endocrinol 47:173–180, 2002
    OpenUrl
  6. ↵
    Yamamoto Y, Hirose H, Saito I, Tomita M, Taniyama M, Matsubara K, Okazaki Y, Ishii T, Nishikai K, Saruta T: Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Science 103:137–142, 2002
    OpenUrlCrossRefPubMed
  7. ↵
    Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Kazuhisa M, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y: Plasma concentration of a novel, adipose-spesific, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595–1599, 2000
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley R, Tataranni PA: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930–1935, 2001
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa JI, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Comm 257:79–83, 1999
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y: Novel modulator for endothelial adhesion molecules. Circulation 100:2473–2476, 1999
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriuyma H, Nagaretani H, Matsuda M, Kondo H, Furuyama N, Kihara S, Nakamura T, Tochino Y, Funahashi T, Matsuzawa Y: Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 51:2734–2741, 2002
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Henry RR: Thiazolidinediones. Endocrinol Metab Clin North Am 26:553–573, 1997
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    Yu J, Javorschi S, Hevener A, Krusczynska Y, Norman R, Sinha M, Olefsky J: The effects of thiazolidinediones on plasma levels of adiponectin in normal, obese, and type 2 diabetic subjects. Diabetes: 51:2968–2974, 2002
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, Matsuzawa Y, Wang JP, Chen CL, Tai TY, Chuang LM: Synthetic peroxisome proliferator–activated receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 25:376–380, 2002
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, Okamoto Y, Ohashi, K, Nagaretani H, Kishida K, Nishizawa H, Maeda N, Kobayashi H, Hiraaoka H, Matsuzawa Yl: Reciprocal association of C- reactive protein with adiponectin in blood stream and adipose tissue. Circulation 107:671–674, 2003
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Fasshauer M, Kralisch S, Klier M, Lossner U, Bluher M, Klein J, Pasche R: Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3–L1 adipocytes. Biochem Biophys Res Comm 301:1045–1050, 2003
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    Engeli S, Feldpausch M, Gorzelniak K, Hartwig F, Heintze U, Janke J, Möhlig M, Pfeiffer AFH, Luft FC, Sharma AM: Association between adiponectin and mediators of inflammation in obese women. Diabetes 52:942–947, 2003
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Zoccali C, Mallamaci F, Panuccio V, Tripepi G, Cutrupi S, Parlongo S, Catalano F, Tanaka S, Ouchi N: Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. Kidney Int 63(Suppl. 84):S98–S102, 2003
    OpenUrl
  19. ↵
    Stenvinkel P, Marchlewska A, Pecoits-Filho R, Heimburger O, Zhang Z, Hoff C, Holmes C, Axelsson J, Arvidsson S, Schalling M, Barany P, Lindholm B, Nordfors L: Adiponectin in renal disease: relationship to phenotype and genetic variation in the gene encoding adiponectin. Kidney Int 65:274–281, 2004
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    Imagawa A, Funahashi T, Nakamura T, Moriwaki M, Tanaka S, Nishizawa H, Sayama K, Uno S, Iwahashi H, Yamagata K, Miyagawa J, Matsuzawa Y: Elevated serum concentration of adipose-derived factor, adiponectin, in patients with type 1 diabetes. Diabetes Care 25:1665–1666, 2002
    OpenUrlFREE Full Text
  21. ↵
    Williams KV, Erbey JR, Becker D, Arslanian S, Orchard TJ: Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes 49:626–632, 2000
    OpenUrlAbstract
  22. ↵
    Cockroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41, 1976
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    Höyby C, Bruun JM, Richelsen B, Flyvbjerg A, Frystyk J: Serum adiponectin levels in adults with Prader-Willi syndrome are independent of anthropometrical parameters and do not change with GH treatment. Eur J Endocrinol 151:457–461, 2004
    OpenUrlAbstract
  24. ↵
    Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S, Hara K, Hada Y, Vasseur F, Froguel P, Kimura S, Nagai R, Kadowaki T: Impaired multimerization of human adiponectin mutants associated with diabetes. J Biol Chem 278:40352–40363, 2003
    OpenUrlAbstract/FREE Full Text
  25. ↵
    Zoccali C, Mallamaci F, Tripepi G, Benedetto F, Cutrupi S, Parlongo S, Malatino L, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Buemi M, Nococia G, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y: Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13:134–141, 2002
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Guebre-Egziabher F, Bernhard J, Funahashi T, Hadj-Aissa A, Fouque D: Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Nephrol Dial Transplant 20:129–134, 2005
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Furuhashi M, Ura N, Katsuhiro H, Hideyaki M, Marenao T, Norihito M, Daisuke Y, Kazuaki S: Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 42:76–81, 2003
    OpenUrlAbstract/FREE Full Text
  28. ↵
    Wang Y, Xu A, Knight C, Xu L, Cooper G: Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin. J Biol Chem 277:19521–19529, 2002
    OpenUrlAbstract/FREE Full Text
  29. ↵
    Chudek J, Adamczak M, Karkoszka H, Budzinski G, Ignacy W, Funahashi T, Matsuzawa Y, Cierpka L, Kokot F, Wiecek A: Plasma adiponectin concentration before and after successful kidney transplantion. Trans Proc 35:2186–2189, 2003
    OpenUrlCrossRef
  30. ↵
    Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ: Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 278:45021–45026, 2003
    OpenUrlAbstract/FREE Full Text
  31. ↵
    Looker HC, Krakoff J, Funahashi T, Matsuzawa Y, Tanaka S, Nelson RG, Knowler WC, Lindsay RS, Hanson RL: Adiponectin concentrations are influenced by renal function and diabetes duration in Pima Indians with type 2 diabetes. J Clin Endocrinol Metab 89:4010–4017, 2004 1999
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Diabetes Care: 28 (6)

In this Issue

June 2005, 28(6)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Serum Adiponectin Is Increased in Type 1 Diabetic Patients With Nephropathy
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Serum Adiponectin Is Increased in Type 1 Diabetic Patients With Nephropathy
Markku Saraheimo, Carol Forsblom, Johan Fagerudd, Anna-Maija Teppo, Kim Pettersson-Fernholm, Jan Frystyk, Allan Flyvbjerg, Per-Henrik Groop
Diabetes Care Jun 2005, 28 (6) 1410-1414; DOI: 10.2337/diacare.28.6.1410

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Serum Adiponectin Is Increased in Type 1 Diabetic Patients With Nephropathy
Markku Saraheimo, Carol Forsblom, Johan Fagerudd, Anna-Maija Teppo, Kim Pettersson-Fernholm, Jan Frystyk, Allan Flyvbjerg, Per-Henrik Groop
Diabetes Care Jun 2005, 28 (6) 1410-1414; DOI: 10.2337/diacare.28.6.1410
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • CONCLUSIONS
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Insulin Resistance Is Associated With Enhanced Brain Glucose Uptake During Euglycemic Hyperinsulinemia: A Large-Scale PET Cohort
  • Restoration of Hypoglycemia Awareness Alters Brain Activity in Type 1 Diabetes
  • Processes Underlying Glycemic Deterioration in Type 2 Diabetes: An IMI DIRECT Study
Show more Pathophysiology/Complications

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.